Overview of Currently Used Chemosensitivity Test Systems in Gynecologic Malignancies and Breast Cancer

1994 ◽  
pp. 12-23 ◽  
Author(s):  
O. R. Köchli ◽  
B.-U. Sevin ◽  
H. E. Averette ◽  
U. Haller
Keyword(s):  
Breast Cancer ◽  
Chemosensitivity Test ◽  
Gynecologic Malignancies ◽  
Test Systems

Comparison of the Effect of Progesterone, Medroxyprogesterone Acetate and Norethisterone on the Proliferation of Human Breast Cancer Cells

2003 ◽  
Vol 9 (1) ◽  
pp. 36-38
Author(s):  
Harald Seeger ◽  
Diethelm Wallwiener ◽  
Alfred O Mueck
Keyword(s):  
Breast Cancer ◽  
Cell Proliferation ◽  
Breast Cancer Risk ◽  
Cancer Risk ◽  
Medroxyprogesterone Acetate ◽  
Human Breast Cancer ◽  
Chemosensitivity Test ◽  
Human Breast ◽  
Long Term Treatment

Objective To investigate in vitro the influence of the three most used progestogens in continuous combined HRT on cell proliferation of the human breast cancer cell line MCF-7. Study design Progesterone (P), medroxyprogesterone acetate (MPA) and norethisterone (NET) were investigated in the range of 0.01 nM to 10 μM alone and in combination with 10 nM oestradiol. Cell proliferation was measured after seven days using the ATP-chemosensitivity test. Results P alone reduced cell proliferation by 20 and 40% at 10−7 and 10−5 M. MPA and NET displayed a significant inhibition of cell proliferation between 20 and 25% for MPA and 23 and 41% for NET over the whole concentration range tested. The effect was greatest at 10−7 M for MPA and at 10−9 M for NET. In combination with oestradiol, P still significantly reduced cell proliferation, the values being between 12 and 61%. For MPA too an inhibitory effect between 20 and 40% was found, whereas for NET the values were between 23 and 38%. Conclusions Our in vitro results indicate that the influence on breast cancer risk using HRT in postmenopausal women may depend on the type of progestogen used as well as on the regimen applied. However, the inhibitory in vitro net effect of the progestogens at clinically relevant dosages is rather minimal and it remains uncertain as to whether progestogens generally may reduce breast cancer risk in long-term treatment. Further clinical trials are urgently required to determine the appropriate choice - if any - of progestogen to complement HRT.

Qualitative and Quantitative Assessment of Taste and Smell Changes in Patients Undergoing Chemotherapy for Breast Cancer or Gynecologic Malignancies

2009 ◽  
Vol 27 (11) ◽  
pp. 1899-1905 ◽  
Author(s):  
Silke Steinbach ◽  
Thomas Hummel ◽  
Christina Böhner ◽  
Sabina Berktold ◽  
Walter Hundt ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Quality Of Life ◽  
Weight Loss ◽  
Chemotherapeutic Agent ◽  
Therapy Response ◽  
Olfactory Function ◽  
Gynecologic Malignancies ◽  
Taste Changes ◽  
Gustatory Function

PurposeSmell and taste changes during chemotherapy are significant complaints of cancer patients. Loss of olfactory/gustatory function can lead to malnutrition, weight loss, and possibly a prolonged morbidity of chemotherapy-induced adverse effects, decreased quality of life, poor compliance, and even decreased therapy response. This prospective study comprehensively investigated, to our knowledge for the first time, smell and taste changes in a cohort of 87 patients undergoing chemotherapy for breast cancer or gynecologic malignancies.Patients and MethodsOlfactory function was tested using Sniffin' Sticks (Burghart; Wedel, Germany) and gustatory function was tested using taste strips before, during, and immediately and 3 months after chemotherapy.ResultsOlfactory and gustatory function significantly decreased during chemotherapy and recovered almost completely 3 months after chemotherapy. Scores of odor thresholds were affected more than those of discrimination or identification. The olfactory function of older patients was affected more than that of younger patients. There was no difference in the olfactory function during chemotherapy with respect to the chemotherapeutic agent or initial diagnosis (breast or ovarian cancer). Regarding taste, scores of salty taste were affected more than scores of sweet, sour, or bitter taste. The gustatory function did not differ significantly during chemotherapy with respect to age or diagnosis but did differ with respect to the chemotherapeutic agent. Taxane-based chemotherapy caused the most severe disorders.ConclusionChemotherapy has a significant but transient effect on olfactory and gustatory function, possibly causing reduced appetite, a low energy intake, and weight loss. Additional spices and flavoring may compensate for this diminished chemosensory function, enhancing patient compliance and quality of life.

scholarly journals Locoregional Therapies for the Treatment of Hepatic Metastases from Breast and Gynecologic Cancers

2018 ◽  
Vol 35 (01) ◽  
pp. 029-034 ◽  
Author(s):  
Samdeep Mouli ◽  
Ramona Gupta ◽  
Neil Sheth ◽  
Andrew Gordon ◽  
Robert Lewandowski
Keyword(s):  
Breast Cancer ◽  
Hepatic Metastases ◽  
The United States ◽  
Locoregional Therapy ◽  
Cancer Death ◽  
Gynecologic Malignancies ◽  
Curative Surgery ◽  
Locoregional Therapies ◽  
Disseminated Disease

AbstractBreast cancer is the most common women's malignancy in the United States and is the second leading cause of cancer death. More than half of patients with breast cancer will develop hepatic metastases; this portends a poorer prognosis. In the appropriately selected patient, there does appear to be a role for curative (surgery, ablation) or palliative (intra-arterial treatments) locoregional therapy. Gynecologic malignancies are less common and metastases to the liver are most often seen in the setting of disseminated disease. The role of locoregional therapies in these patients is not well reported. The purpose of this article is to review the outcomes data of locoregional therapies in the treatment of hepatic metastases from breast and gynecologic malignancies.

Sign in / Sign up

Export Citation Format

Share Document